Dogwood Therapeutics (NASDAQ:DWTX) · earnings miss
Quarter
Q2
EPS estimate to actual
-$0.14→ to -$0.34
Revenue estimate to actual
$0.0→ to $0.0
At a glance
Key takeaways
01Dogwood Therapeutics reported Q2 2026 earnings per share of -$0.34, missing the consensus estimate of -$0.14 by $0.20 per share, representing a 143% miss relative to expectations.
02The company's stock trades at $1.98 with a market capitalization of $12.0 million following the earnings release.
03This marks a deterioration from Q1 2026 when the company beat estimates by $0.05 per share, suggesting a worsening trend in quarterly performance.
Earnings Results
Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly earnings results on August 13, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $-0.34, missing the consensus estimate of $-0.14 by $0.20 per share. Revenue came in at , meeting the estimate of .
Company Overview
Dogwood Therapeutics's stock moved following the earnings release. The stock currently trades at $1.98 with a market capitalization of $12.0M.
Missing analyst estimates puts pressure on a stock as investors reassess their growth assumptions. The market's reaction to an earnings miss depends heavily on the magnitude of the shortfall, the company's forward guidance, and whether the miss was driven by temporary or structural factors.
The 143% miss relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Dogwood Therapeutics should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.